Water Proton NMR for In Situ Detection of Insulin Aggregates.

The need for quality control during the manufacturing and distribution of biopharmaceuticals is becoming increasingly necessary. At present, detecting drug degradation through the monitoring of active factor aggregation is accomplished through "invasive" techniques, such as size-exclusion chromatography (SEC), analytical ultracentrifugation (AUC), and so on. Unfortunately, these analytical methods require sampling the drug by opening the drug container that renders the remaining drug unusable regardless of the outcome of the test. Visual inspection, the current non-invasive quality control method is qualitative and can only detect visible particulates. Thus, it will miss sub-visible protein aggregates. In this paper, human insulin preparations were used to demonstrate that the transverse relaxation rate of water protons R2 ((1) H2 O) can serve as a sensitive and reliable indicator to detect and quantify both visible and sub-visible protein aggregates. R2 ((1) H2 O) is measured using a wide-bore low-field bench-top NMR instrument with permanent magnets. Such analysis could be carried out without opening the drug container, thus saving a drug for further use. The results suggest a novel, economical, non-destructive in situ analytical technique that allows for on-the-site quantification of protein aggregation in biopharmaceutical products.

[1]  N. Wagner,et al.  Viscosimetric, Hydrodynamic, and Conformational Properties of Dendrimers and Dendrons , 2001 .

[2]  S. Joshi,et al.  Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. , 2014, Biologicals : journal of the International Association of Biological Standardization.

[3]  S. Provencher,et al.  Global Analysis of Dynamic Light Scattering Autocorrelation Functions , 1996 .

[4]  Ipsita Roy,et al.  Probing the mechanism of insulin aggregation during agitation. , 2011, International journal of pharmaceutics.

[5]  Daniela Verthelyi,et al.  Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.

[6]  Z. Zeng,et al.  Structure of an insulin dimer in an orthorhombic crystal: the structure analysis of a human insulin mutant (B9 Ser-->Glu). , 1999, Acta crystallographica. Section D, Biological crystallography.

[7]  J. Tamada,et al.  Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[9]  J. Hedrick,et al.  Constitutional Isomers of Dendrimer-like Star Polymers: Design, Synthesis, and Conformational and Structural Properties , 2000 .

[10]  V. Villari,et al.  Study of the aggregation of insulin glargine by light scattering. , 2006, Journal of pharmaceutical sciences.

[11]  Wei Wang,et al.  Immunogenicity of protein aggregates--concerns and realities. , 2012, International journal of pharmaceutics.

[12]  B. Berne,et al.  Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics , 1976 .

[13]  I. L. Fabelinskii,et al.  Molecular scattering of light , 1968 .

[14]  Srivalli Telikepalli,et al.  Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress. , 2015, Journal of pharmaceutical sciences.

[15]  R. Feldstein,et al.  Ultra-Rapid Absorption of Recombinant Human Insulin Induced by Zinc Chelation and Surface Charge Masking , 2012, Journal of diabetes science and technology.

[16]  Peter S. Belton,et al.  The effects of proteins on the proton N.M.R. transverse relaxation time of water , 1989 .

[17]  W WarneNicholas,et al.  Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011 .

[18]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[19]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[20]  E. Topp Commentary: Current Perspectives on the Aggregation of Protein Drugs , 2014, The AAPS Journal.

[21]  G. Rotilio,et al.  pH dependece of the nuclear magnetic relaxation rate of solvent water protons in solutions of bovine superoxide dismutase. , 1974, Biochimica et biophysica acta.

[22]  J. J. Led,et al.  Solution structures of the R6 human insulin hexamer,. , 1997, Biochemistry.

[23]  H. Abramson,et al.  THE ISOELECTRIC POINT OF INSULIN ELECTRICAL PROPERTIES OF ADSORBED AND CRYSTALLINE INSULIN , 1933 .

[24]  L. Palmieri,et al.  A T3R3 hexamer of the human insulin variant B28Asp. , 2013, Biophysical chemistry.

[25]  D. A. Ivanov,et al.  Mesoscale Inhomogeneities in Aqueous Solutions of 3-Methylpyridine and Tertiary Butyl Alcohol , 2011 .

[26]  J. Brange,et al.  Insulin structure and stability. , 1993, Pharmaceutical biotechnology.

[27]  Ping Wang,et al.  Impact of illegal trade on the quality of epoetin alfa in Thailand. , 2009, Clinical therapeutics.

[28]  Linda O Narhi,et al.  Classification of protein aggregates. , 2012, Journal of pharmaceutical sciences.

[29]  J. Hennel,et al.  Proton Magnetic Relaxation and Protein Hydration , 1963, Nature.

[30]  M. Bardor,et al.  Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins , 2012, Biotechnology journal.

[31]  M. Taraban,et al.  Water proton NMR-a sensitive probe for solute association. , 2015, Chemical communications.

[32]  J. Philo,et al.  A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.